CRDF (Cardiff Oncology) Beginning Cash Position: $17.47 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
26 GF Score
Price $0.84
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Beginning Cash Position?

Cardiff Oncology CRDF -2.58% 26 Beginning Cash Position is $17.47 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Cardiff Oncology's Beginning Cash Position for the quarter that ended in Mar. 2026 was $17.47 Mil.

Cardiff Oncology's quarterly Beginning Cash Position declined from Sep. 2025 ($10.78 Mil) to Dec. 2025 ($10.14 Mil) but then increased from Dec. 2025 ($10.14 Mil) to Mar. 2026 ($17.47 Mil).

Cardiff Oncology's annual Beginning Cash Position increased from Dec. 2023 ($16.35 Mil) to Dec. 2024 ($21.66 Mil) and increased from Dec. 2024 ($21.66 Mil) to Dec. 2025 ($51.47 Mil).

Cardiff Oncology Beginning Cash Position Related Terms

Cardiff Oncology Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Beginning Cash Position Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.98 11.94 16.35 21.66 51.47

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.47 24.10 10.78 10.14 17.47
CRDF
26GF Score
Cardiff Oncology Inc CRDF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $17.47 Mil mean?
Cardiff Oncology (CRDF) has a Beginning Cash Position of $17.47 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Beginning Cash Position too high?
Cardiff Oncology's current Beginning Cash Position is $17.47 Mil. Overall, Cardiff Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Beginning Cash Position compare to MAIA and TELO?
Cardiff Oncology's Beginning Cash Position of $17.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Beginning Cash Position is $17.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current Beginning Cash Position of $17.47 Mil. The current Beginning Cash Position is $17.47 Mil. Cardiff Oncology's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Beginning Cash Position is $17.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
26GF Score

Get the complete analysis for CRDF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.84
Price